MarketCap
Facebook
X
TelegramAnnual report 2021
added 12-16-2023
Arena Pharmaceuticals Cash Conversion Cycle 2011-2025 | ARNA
Annual Cash Conversion Cycle Arena Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 946 | 1.53 | 75.6 | 193 | 76.8 | 253 | 412 | 581 | 290 | -89.1 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 946 | -89.1 | 274 |
Quarterly Cash Conversion Cycle Arena Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | 335 | 50.9 | 119 | 219 | 0.47 | 53.7 | 130 | 116 | 194 | 14 | 89.1 | 113 | 80.5 | 13.7 | 95.6 | 193 | 116 | 58.1 | 49.3 | 49 | 32.2 | 36.9 | 41.5 | 26.5 | 95.8 | 148 | 270 | 14 | 311 | 262 | 341 | 23.1 | 128 | 26.7 | 16 | 17 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 341 | 0.47 | 108 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aclaris Therapeutics
ACRS
|
-881 | $ 3.0 | -0.99 % | $ 232 M |  USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
12 | $ 1.1 | -3.51 % | $ 6 M |  China |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-2.85 K | - | -11.43 % | $ 502 K | USA |
 |
BioDelivery Sciences International
BDSI
|
340 | - | -4.8 % | $ 255 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Bellicum Pharmaceuticals
BLCM
|
6.09 | - | -9.72 % | $ 5.89 M | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M |  Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M | Britain |
 |
Berkeley Lights
BLI
|
214 | - | -7.31 % | $ 87 M | USA |
 |
Albireo Pharma
ALBO
|
-1.55 K | - | -0.23 % | $ 916 M | USA |
 |
Catalyst Biosciences
CBIO
|
391 | $ 12.12 | -1.86 % | $ 798 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
166 | $ 26.86 | -0.96 % | $ 1.3 B | USA |
 |
BeiGene, Ltd.
BGNE
|
49.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
28.8 | - | -10.95 % | $ 876 K | USA |
 |
Anika Therapeutics
ANIK
|
270 | $ 9.53 | -0.21 % | $ 140 M | USA |
 |
Certara
CERT
|
78.4 | $ 8.85 | -0.45 % | $ 1.42 B | USA |
 |
bluebird bio
BLUE
|
-54.4 | - | - | $ 546 M | USA |
 |
Cellectis S.A.
CLLS
|
-839 | $ 4.95 | 4.2 % | $ 116 M |  France |
 |
Axon Enterprise
AXON
|
86.2 | $ 583.1 | -0.13 % | $ 44.2 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M |  Israel |
 |
Aytu BioScience
AYTU
|
174 | $ 2.55 | 4.08 % | $ 16 M | USA |
 |
AstraZeneca PLC
AZN
|
-58 | $ 92.68 | -0.24 % | $ 96.9 B | Britain |
 |
ChromaDex Corporation
CDXC
|
23.8 | - | -0.88 % | $ 598 M | USA |
 |
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
149 | - | -5.38 % | $ 6.06 M | USA |
 |
Celldex Therapeutics
CLDX
|
-6.08 K | $ 25.93 | -1.8 % | $ 1.67 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
209 | $ 11.43 | 2.65 % | $ 739 M | USA |